A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Nevanimibe (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Therapeutic Use
- Sponsors Millendo Therapeutics
- 13 Nov 2019 According to a Millendo Therapeutics media release, top-line results from cohort 1 of this trial are expected in the second half of 2020.
- 12 Aug 2019 According to a Millendo Therapeutics media release, the trial is now recruiting patients under an amended protocol. An update on the study timelines is planned for 2H19.
- 12 Aug 2019 According to a Millendo Therapeutics media release, the protocol of this trial has been amended to include a 500 mg BID (twice a day) starting dose and an extension of the study treatment period to 16 weeks.